Terumo (4543) Acquisition presentation summary

Deal rationale and strategic fit

• Acquisition targets a clinical-stage biomaterials company specializing in next-generation liquid embolics for chronic subdural hematoma (cSDH).

• Expands into adjacent markets, reinforcing a mission to preserve and restore brain health.

• Converts a prior investment in NeoCast into full ownership, leveraging existing clinical and regulatory capabilities.

• Integrates NeoCast with an established liquid embolic portfolio, offering a comprehensive solution for physician preferences.

Financial terms and conditions

• Financial terms of the acquisition were not disclosed.

• Transaction funded with cash on hand; financial impact to be reflected in future disclosures.

Synergies and expected cost savings

• Existing relationships from the current liquid embolic product will serve as the launch channel for NeoCast.

• Portfolio integration expected to streamline offerings across all liquid embolic procedures.